Agile Therapeutics
(NASDAQ) AGRX
Agile Therapeutics Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$21.57M
Net Income (TTM)
$15.86M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
AGRX News
AGRX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Agile Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
19
CEO
Al Altomari, MBA
Website
www.agiletherapeutics.comHeadquarters
Princeton, NJ 08540, US
AGRX Financials
Key Financial Metrics (TTM)
Gross Margin
54%
Operating Margin
-1%
Net Income Margin
-74%
Return on Equity
1%
Return on Capital
2%
Return on Assets
-1%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$10.62M
Operating Income
$19.88M
EBITDA
$12.66M
Operating Cash Flow
$9.58M
Capital Expenditure
$0.00
Free Cash Flow
$9.58M
Cash & ST Invst.
$2.56M
Total Debt
$2.17M
Agile Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$5.58M
+1.3%
Gross Profit
$4.08M
+27.7%
Gross Margin
73.17%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
19
N/A
Net Income
$11.87M
-211.7%
EBITDA
$2.75M
+17.8%
Quarterly Fundamentals
Net Cash
$2.56M
+2712.1%
Accounts Receivable
$4.55M
+2.0%
Inventory
$5.79M
+128.3%
Long Term Debt
$0.00
-100.0%
Short Term Debt
$289.00K
-88.0%
Return on Assets
-1.41%
N/A
Return on Invested Capital
1.89%
N/A
Free Cash Flow
$233.00K
+102.7%
Operating Cash Flow
$233.00K
+102.7%